SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis

Oncotarget

Volumn 7, Issue 43, 2016, Pages 69321-69336

  Akamata, Kaname ^a   Wei, Jun ^a   Bhattacharyya, Mitra ^a   Cheresh, Paul ^a   Bonner, Michael Y ^b   Arbiser, Jack L ^b,c   Raparia, Kirtee ^a   Gupta, Mahesh P ^d   Kamp, David W ^a,e   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

^e JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Fibrosis; Myofibroblast; Pathology Section; ROS; SIRT3; TGF

Indexed keywords

BLEOMYCIN; CHEMICAL COMPOUND; HEXAFLUORO; HONOKIOL; MANGANESE SUPEROXIDE DISMUTASE; REACTIVE OXYGEN METABOLITE; SIRTUIN 3; SMAD2 PROTEIN; SMAD3 PROTEIN; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; FLUORINATED HYDROCARBON;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG BIOPSY; LUNG FIBROBLAST; LUNG FIBROSIS; MALE; MIDDLE AGED; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ACETYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCLERODERMA; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; TISSUE LEVEL; YOUNG ADULT; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; FIBROBLAST; FIBROSIS; GENETICS; LUNG; METABOLISM; PATHOLOGY; RNA INTERFERENCE; SKIN;

ADULT; AGED; ANIMALS; BLEOMYCIN; CELLS, CULTURED; ENZYME ACTIVATION; FEMALE; FIBROBLASTS; FIBROSIS; HUMANS; HYDROCARBONS, FLUORINATED; LUNG; MALE; MICE, INBRED C57BL; MIDDLE AGED; RNA INTERFERENCE; SCLERODERMA, SYSTEMIC; SIRTUIN 3; SKIN;

EID: 84994358593     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.12504     Document Type: Article

References (44)

1. Wynn TA and Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature medicine. 2012; 18(7):1028-1040.
2. Gabrielli A, Avvedimento EV and Krieg T. Scleroderma. The New England journal of medicine. 2009; 360(19):1989-2003.
3. Topal AA and Dhurat RS. Scleroderma therapy: clinical overview of current trends and future perspective. Rheumatol Int. 2013; 33(1):1-18.
4. Bhattacharyya S, Wei J and Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012; 8(1):42-54.
5. Selman M and Pardo A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. American journal of respiratory and critical care medicine. 2014; 189(10):1161-1172.
6. Hu T, Ramachandrarao SP, Siva S, Valancius C, Zhu Y, Mahadev K, Toh I, Goldstein BJ, Woolkalis M and Sharma K. Reactive oxygen species production via NADPH oxidase mediates TGF-beta-induced cytoskeletal alterations in endothelial cells. Am J Physiol Renal Physiol. 2005; 289(4):F816-825.
7. North BJ and Verdin E. Sirtuins: Sir2-related NADdependent protein deacetylases. Genome Biol. 2004; 5(5):224.
8. Michan S and Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J. 2007; 404(1):1-13.
9. Saunders LR and Verdin E. Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene. 2007; 26(37):5489-5504.
10. Lavu S, Boss O, Elliott PJ and Lambert PD. Sirtuins-novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008; 7(10):841-853.
11. Brown K, Xie S, Qiu X, Mohrin M, Shin J, Liu Y, Zhang D, Scadden DT and Chen D. SIRT3 reverses aging-associated degeneration. Cell Rep. 2013; 3(2):319-327.
12. Tao R, Vassilopoulos A, Parisiadou L, Yan Y and Gius D. Regulation of MnSOD enzymatic activity by Sirt3 connects the mitochondrial acetylome signaling networks to aging and carcinogenesis. Antioxidants & redox signaling. 2014; 20(10):1646-1654.
13. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY and Whitfield ML. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. The Journal of investigative dermatology. 2010; 130(3):694-705.
14. Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP, Gius D and Gupta MP. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nature communications. 2015; 6:6656.
15. Singh KK. Mitochondria damage checkpoint, aging, and cancer. Annals of the New York Academy of Sciences. 2006; 1067:182-190.
16. Bresciani G, da Cruz IB and Gonzalez-Gallego J. Manganese superoxide dismutase and oxidative stress modulation. Advances in clinical chemistry. 2015; 68:87-130.
17. Chen Y, Zhang J, Lin Y, Lei Q, Guan KL, Zhao S and Xiong Y. Tumour suppressor SIRT3 deacetylates and activates manganese superoxide dismutase to scavenge ROS. EMBO reports. 2011; 12(6):534-541.
18. Qiu X, Brown K, Hirschey MD, Verdin E and Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell metabolism. 2010; 12(6):662-667.
19. Tao R, Coleman MC, Pennington JD, Ozden O, Park SH, Jiang H, Kim HS, Flynn CR, Hill S, Hayes McDonald W, Olivier AK, Spitz DR and Gius D. Sirt3-mediated deacetylation of evolutionarily conserved lysine 122 regulates MnSOD activity in response to stress. Molecular cell. 2010; 40(6):893-904.
20. Chao LK, Liao PC, Ho CL, Wang EI, Chuang CC, Chiu HW, Hung LB and Hua KF. Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogenactivated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem. 2010; 58(6):3472-3478.
21. Bai X, Cerimele F, Ushio-Fukai M, Waqas M, Campbell PM, Govindarajan B, Der CJ, Battle T, Frank DA, Ye K, Murad E, Dubiel W, SoffG and Arbiser JL. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. The Journal of biological chemistry. 2003; 278(37):35501-35507.
22. Shen JL, Man KM, Huang PH, Chen WC, Chen DC, Cheng YW, Liu PL, Chou MC and Chen YH. Honokiol and magnolol as multifunctional antioxidative molecules for dermatologic disorders. Molecules. 2010; 15(9):6452-6465.
23. Woodbury A, Yu SP, Wei L and Garcia P. Neuromodulating effects of honokiol: a review. Front Neurol. 2013; 4:130.
24. Bonner MY, Karlsson I, Rodolfo M, Arnold RS, Vergani E and Arbiser JL. Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget. 2016. doi: 10.18632/oncotarget.7289.
25. Kim SJ, Cheresh P, Jablonski RP, Williams DB and Kamp DW. The Role of Mitochondrial DNA in Mediating Alveolar Epithelial Cell Apoptosis and Pulmonary Fibrosis. International journal of molecular sciences. 2015; 16(9):21486-21519.
26. Sundaresan NR, Gupta M, Kim G, Rajamohan SB, Isbatan A and Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. The Journal of clinical investigation. 2009; 119(9):2758-2771.
27. Macconi D, Perico L and Benigni A. Mitochondrial Dynamics Is Linked to Longevity and Protects from End-Organ Injury: The Emerging Role of Sirtuin 3. Antioxidants & redox signaling. 2016.
28. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK and Varga J. Rosiglitazone abrogates bleomycininduced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. The American journal of pathology. 2009; 174(2):519-533.
29. Jain M, Rivera S, Monclus EA, Synenki L, Zirk A, Eisenbart J, Feghali-Bostwick C, Mutlu GM, Budinger GR and Chandel NS. Mitochondrial reactive oxygen species regulate transforming growth factor-beta signaling. The Journal of biological chemistry. 2013; 288(2):770-777.
30. Negmadjanov U, Godic Z, Rizvi F, Emelyanova L, Ross G, Richards J, Holmuhamedov EL and Jahangir A. TGF-beta1-mediated differentiation of fibroblasts is associated with increased mitochondrial content and cellular respiration. PloS one. 2015; 10(4):e0123046.
31. Varga J and Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nature reviews Rheumatology. 2009; 5(4):200-206.
32. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, ZasloffM, Marshall JL, Shetty K, Johnson L, Mishra L and He AR. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene. 2009; 28(7):961-972.
33. Wu M and Varga J. In perspective: murine models of scleroderma. Current rheumatology reports. 2008; 10(3):173-182.
34. Mori Y, Chen SJ and Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis and rheumatism. 2003; 48(7):1964-1978.
35. Jinnin M, Ihn H, Mimura Y, Asano Y and Tamaki K. Involvement of the constitutive complex formation of c-Ski/SnoN with Smads in the impaired negative feedback regulation of transforming growth factor beta signaling in scleroderma fibroblasts. Arthritis and rheumatism. 2007; 56(5):1694-1705.
36. Kudryavtseva AV, Krasnov GS, Dmitriev AA, Alekseev BY, Kardymon OL, Sadritdinova AF, Fedorova MS, Pokrovsky AV, Melnikova NV, Kaprin AD, Moskalev AA and Snezhkina AV. Mitochondrial dysfunction and oxidative stress in aging and cancer. Oncotarget. 2016. [Epub ahead of print]. doi: 10.18632/oncotarget.9821.
37. Pillai VB, Bindu S, Sharp W, Fang YH, Kim G, Gupta M, Samant S and Gupta MP. Sirt3 protects mitochondrial DNA damage and blocks the development of doxorubicin-induced cardiomyopathy in mice. American journal of physiology Heart and circulatory physiology. 2016; 310(8):H962-972.
38. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J and Singh AP. Honokiol: a novel natural agent for cancer prevention and therapy. Current molecular medicine. 2012; 12(10):1244-1252.
39. Yu W, Dittenhafer-Reed KE and Denu JM. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. The Journal of biological chemistry. 2012; 287(17):14078-14086.
40. Pedroza M, Le TT, Lewis K, Karmouty-Quintana H, To S, George AT, Blackburn MR, Tweardy DJ and Agarwal SK. STAT-3 contributes to pulmonary fibrosis through epithelial injury and fibroblast-myofibroblast differentiation. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2016; 30(1):129-140.
41. Sosulski ML, Gongora R, Feghali-Bostwick C, Lasky JA and Sanchez CG. Sirtuin 3 Deregulation Promotes Pulmonary Fibrosis. J Gerontol A Biol Sci Med Sci. 2016.
42. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Jr., Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis and rheumatism. 2013; 65(11):2737-2747.
43. Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, Doniparthi S, Tamaki Z, HinchcliffM, Distler JH and Varga J. A synthetic PPAR-gamma agonist triterpenoid ameliorates experimental fibrosis: PPAR-gammaindependent suppression of fibrotic responses. Ann Rheum Dis. 2014; 73(2):446-454.
44. Wei J, Ghosh AK, Chu H, Fang F, HinchcliffME, Wang J, Marangoni RG and Varga J. The Histone Deacetylase Sirtuin 1 Is Reduced in Systemic Sclerosis and Abrogates Fibrotic Responses by Targeting Transforming Growth Factor beta Signaling. Arthritis Rheumatol. 2015; 67(5):1323-1334.